These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35580380)

  • 41. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations.
    Wu J; Zhang HX; Zhang J
    Phys Chem Chem Phys; 2023 Jan; 25(3):2304-2319. PubMed ID: 36597957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging vaccine-breakthrough SARS-CoV-2 variants.
    Wang R; Chen J; Hozumi Y; Yin C; Wei GW
    ArXiv; 2021 Sep; ():. PubMed ID: 34518803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity.
    Kumar V; Singh J; Hasnain SE; Sundar D
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain.
    Patrick C; Upadhyay V; Lucas A; Mallela KMG
    J Mol Biol; 2022 Jul; 434(13):167622. PubMed ID: 35533762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
    Seephetdee C; Bhukhai K; Buasri N; Leelukkanaveera P; Lerdwattanasombat P; Manopwisedjaroen S; Phueakphud N; Kuhaudomlarp S; Olmedillas E; Saphire EO; Thitithanyanont A; Hongeng S; Wongtrakoongate P
    Antiviral Res; 2022 Aug; 204():105370. PubMed ID: 35772601
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using
    Boon SS; Xia C; Wang MH; Yip KL; Luk HY; Li S; Ng RWY; Lai CKC; Chan PKS; Chen Z
    mBio; 2021 Oct; 12(5):e0268721. PubMed ID: 34700382
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants.
    Laffeber C; de Koning K; Kanaar R; Lebbink JHG
    J Mol Biol; 2021 Jul; 433(15):167058. PubMed ID: 34023401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.
    Gan HH; Twaddle A; Marchand B; Gunsalus KC
    J Mol Biol; 2021 Jul; 433(15):167051. PubMed ID: 33992693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
    Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
    Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody evasion by the P.1 strain of SARS-CoV-2.
    Dejnirattisai W; Zhou D; Supasa P; Liu C; Mentzer AJ; Ginn HM; Zhao Y; Duyvesteyn HME; Tuekprakhon A; Nutalai R; Wang B; López-Camacho C; Slon-Campos J; Walter TS; Skelly D; Costa Clemens SA; Naveca FG; Nascimento V; Nascimento F; Fernandes da Costa C; Resende PC; Pauvolid-Correa A; Siqueira MM; Dold C; Levin R; Dong T; Pollard AJ; Knight JC; Crook D; Lambe T; Clutterbuck E; Bibi S; Flaxman A; Bittaye M; Belij-Rammerstorfer S; Gilbert SC; Carroll MW; Klenerman P; Barnes E; Dunachie SJ; Paterson NG; Williams MA; Hall DR; Hulswit RJG; Bowden TA; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
    Cell; 2021 May; 184(11):2939-2954.e9. PubMed ID: 33852911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
    Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ
    PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus.
    Saied AA; Nascimento MSL; do Nascimento Rangel AH; Skowron K; Grudlewska-Buda K; Dhama K; Shah J; Abdeen A; El-Mayet FS; Ahmed H; Metwally AA
    J Med Virol; 2022 Oct; 94(10):4599-4610. PubMed ID: 35655326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects.
    Lusvarghi S; Wang W; Herrup R; Neerukonda SN; Vassell R; Bentley L; Eakin AE; Erlandson KJ; Weiss CD
    J Virol; 2022 Jan; 96(1):e0111021. PubMed ID: 34668774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allosteric Cross-Talk among Spike's Receptor-Binding Domain Mutations of the SARS-CoV-2 South African Variant Triggers an Effective Hijacking of Human Cell Receptor.
    Spinello A; Saltalamacchia A; Borišek J; Magistrato A
    J Phys Chem Lett; 2021 Jul; 12(25):5987-5993. PubMed ID: 34161095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.